LAMC2 and pancreatic neoplasm: Subsequently, Okada et al. identified that LAMC2 not only correlates with OS in pancreatic cancer but also modulates gemcitabine sensitivity (Okada et al., 2021), suggesting that LAMC2 is a promising target in pancreatic cancer.